 |
      
|
|
|
|
|
|||||
|
|
June 23, 2003
Neurochem Conference Call and WebCast on Alzhemed™ Phase II Study for
Alzheimer's Disease at 10:00AM today.. About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics
for neurological disorders. The Company's staged pipeline of proprietary,
disease-modifying, oral products addresses critical unmet medical needs. Fibrillex™,
designated an orphan drug, is in a pivotal Phase II/III clinical trial for AA amyloidosis.
Alzhemed™ has completed a Phase II clinical trial. Cerebril™ is in a Phase II
trial for the prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy.
Neurochem is also developing a product for the potential treatment of epileptic seizures
induced by traumatic brain injury. For additional information on Neurochem, please visit
our website at: (www.neurochem.com).
All of the statements contained in this news release, other than statements of fact which
are independently verifiable at the date hereof, are forward-looking statements. Such
statements, based as they are on the current expectations of management, inherently involve
numerous risks and uncertainties, known and unknown. Some examples of known risks are: the
impact of general economic conditions, general conditions in the pharmaceutical industry, changes
in the regulatory environment in the jurisdictions in which Neurochem does business, stock
market volatility, fluctuations in costs, and changes to the competitive environment due to
consolidation or otherwise. Consequently, actual future results may differ materially from
the anticipated results expressed in the forward-looking statements.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
